Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report)’s stock price was down 3.8% during trading on Tuesday . The stock traded as low as $13.61 and last traded at $13.61. Approximately 1,520 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 69,687 shares. The stock had previously closed at $14.15.
Gyre Therapeutics Price Performance
The business’s 50 day moving average is $12.95 and its 200 day moving average is $13.13.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The business had revenue of $25.23 million during the quarter. Analysts forecast that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Gyre Therapeutics
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Stories
- Five stocks we like better than Gyre Therapeutics
- 3 Best Fintech Stocks for a Portfolio Boost
- WD-40 Company Gears Up for a Double-Digit Stock Advance
- Using the MarketBeat Dividend Yield Calculator
- Monster and Celsius Energized: Which Stock Offers More Upside?
- What is the Dow Jones Industrial Average (DJIA)?
- Sherwin-Williams Plunges Into Buying Opportunity: Time to Buy?
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.